Below are the financial statements of Santen Pharmaceutical, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in billions of JPY | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| For the year | — | — | — | — | — |
| Revenue | 301.97a | 279.04a | 266.26a | 249.61a | 241.56a |
| Cost of sales | -123.26a | -112.95a | -109.67a | -98.22a | -94.83a |
| Selling, general and administrative expenses | -91.53a | -96.26a | -84.5a | -79.55a | -73.36a |
| Research and development expenses | -25.42a | -28.3a | -26.38a | -24.11a | -23.34a |
| Operating profit/loss | 38.54a | -3.09a | 35.89a | 12.19a | 33.54a |
| Core operating profit | 62.78a | 44.24a | 46.35a | 50.1a | 50.02a |
| Income tax expenses | -3.17a | -9.18a | -8.43a | -2.56a | -10.38a |
| Net profit/loss for the year | 26.7a | -14.98a | 27.19a | 9.13a | 21.71a |
| Core net profit for the year | 48.51a | 33.24a | 35.2a | 37.55a | 35.89a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.